Acorn Financial Advisory Services Inc. ADV Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

Acorn Financial Advisory Services Inc. ADV grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 14.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,399 shares of the medical device company’s stock after buying an additional 1,814 shares during the quarter. Acorn Financial Advisory Services Inc. ADV’s holdings in DexCom were worth $965,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in DXCM. CWA Asset Management Group LLC purchased a new position in DexCom during the 3rd quarter valued at about $222,000. Comprehensive Financial Consultants Institutional Inc. raised its holdings in shares of DexCom by 13.5% during the third quarter. Comprehensive Financial Consultants Institutional Inc. now owns 7,334 shares of the medical device company’s stock valued at $492,000 after acquiring an additional 874 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in DexCom in the third quarter valued at $280,000. Quintet Private Bank Europe S.A. increased its position in DexCom by 324.1% during the 3rd quarter. Quintet Private Bank Europe S.A. now owns 4,105 shares of the medical device company’s stock valued at $275,000 after purchasing an additional 3,137 shares during the period. Finally, QRG Capital Management Inc. raised its holdings in DexCom by 8.6% in the 3rd quarter. QRG Capital Management Inc. now owns 15,697 shares of the medical device company’s stock worth $1,052,000 after purchasing an additional 1,248 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

NASDAQ DXCM traded up $1.05 on Friday, reaching $69.96. 3,153,680 shares of the stock were exchanged, compared to its average volume of 4,825,686. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market capitalization of $27.33 billion, a PE ratio of 41.89, a PEG ratio of 2.10 and a beta of 1.17. The company’s 50-day simple moving average is $69.66 and its two-hundred day simple moving average is $93.70.

Analyst Ratings Changes

Several analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Oppenheimer dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price objective on shares of DexCom in a report on Tuesday, July 23rd. Finally, Robert W. Baird raised their price target on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $104.59.

Insider Activity at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.